These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 25532028)

  • 21. Use of a booster dose of capsular group C meningococcal glycoconjugate vaccine to demonstrate immunologic memory in children primed with one or two vaccine doses in infancy.
    Pace D; Khatami A; Attard-Montalto S; Voysey M; Finn A; Faust SN; Heath PT; Borrow R; Snape MD; Pollard AJ
    Vaccine; 2016 Dec; 34(50):6350-6357. PubMed ID: 28029540
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of meningococcal C conjugate vaccination programs with and without catch-up campaigns in adolescents: Lessons learned from Bahia, Brazil.
    Evellyn do Macedo L; Ferreira VM; Feitosa CA; Nunes AMPB; Campos LC; Sáfadi MAP
    Hum Vaccin Immunother; 2018 May; 14(5):1131-1137. PubMed ID: 29236585
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Salivary antibody levels in adolescents in response to a meningococcal serogroup C conjugate booster vaccination nine years after priming: systemically induced local immunity and saliva as potential surveillance tool.
    Stoof SP; van der Klis FR; van Rooijen DM; Bogaert D; Trzciński K; Sanders EA; Berbers GA
    Vaccine; 2015 Jul; 33(32):3933-9. PubMed ID: 26100925
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Persistence of serogroup C antibody responses following quadrivalent meningococcal conjugate vaccination in United States military personnel.
    Patel M; Romero-Steiner S; Broderick MP; Thomas CG; Plikaytis BD; Schmidt DS; Johnson SE; Milton AS; Carlone GM; Clark TA; Messonnier NE; Cohn AC; Faix DJ
    Vaccine; 2014 Jun; 32(30):3805-9. PubMed ID: 24837781
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Age-related disparity in functional activities of human group C serum anticapsular antibodies elicited by meningococcal polysaccharide vaccine.
    Harris SL; King WJ; Ferris W; Granoff DM
    Infect Immun; 2003 Jan; 71(1):275-86. PubMed ID: 12496177
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety and immunogenicity of a booster dose of meningococcal (groups A, C, W, and Y) polysaccharide diphtheria toxoid conjugate vaccine.
    Robertson CA; Greenberg DP; Hedrick J; Pichichero M; Decker MD; Saunders M
    Vaccine; 2016 Oct; 34(44):5273-5278. PubMed ID: 27642132
    [TBL] [Abstract][Full Text] [Related]  

  • 27. B cell memory to a serogroup C meningococcal conjugate vaccine in childhood and response to booster: little association with serum IgG antibody.
    Perrett KP; Jin C; Clutterbuck E; John TM; Winter AP; Kibwana E; Yu LM; Curtis N; Pollard AJ
    J Immunol; 2012 Sep; 189(5):2673-81. PubMed ID: 22855707
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effectiveness of a Serogroup B and C Meningococcal Vaccine Developed in Cuba.
    Ochoa-Azze RF; García-Imía L; Vérez-Bencomo V
    MEDICC Rev; 2018 Jul; 20(3):22-29. PubMed ID: 31242158
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Concomitant administration of a fully liquid ready-to-use DTaP-IPV-HB-PRP-T hexavalent vaccine with a meningococcal ACWY conjugate vaccine in toddlers.
    Vesikari T; Borrow R; Da Costa X; Thomas S; Eymin C; Boisnard F; Lockhart S
    Vaccine; 2018 Dec; 36(52):8019-8027. PubMed ID: 30471953
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A randomized study comparing the safety and immunogenicity of a conjugate vaccine combination containing meningococcal group C and pneumococcal capsular polysaccharide--CRM197 with a meningococcal group C conjugate vaccine in healthy infants: challenge phase.
    Riddell A; Buttery JP; McVernon J; Chantler T; Lane L; Bowen-Morris J; Diggle L; Morris R; Lockhart S; Pollard AJ; Cartwright K; Moxon ER
    Vaccine; 2007 May; 25(19):3906-12. PubMed ID: 17368663
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antibody Persistence in Young Children 5 Years after Vaccination with a Combined Haemophilus influenzae Type b-Neisseria meningitidis Serogroup C Conjugate Vaccine Coadministered with Diphtheria-Tetanus-Acellular Pertussis-Based and Pneumococcal Conjugate Vaccines.
    Tejedor JC; Brzostek J; Konior R; Grunert D; Kolhe D; Baine Y; Van Der Wielen M
    Clin Vaccine Immunol; 2016 Jul; 23(7):555-63. PubMed ID: 27145999
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunogenicity and safety of meningococcal C conjugate vaccine in children and adolescents infected and uninfected with HIV in Rio de Janeiro, Brazil.
    Frota AC; Milagres LG; Harrison LH; Ferreira B; Menna Barreto D; Pereira GS; Cruz AC; Pereira-Manfro W; de Oliveira RH; Abreu TF; Hofer CB
    Pediatr Infect Dis J; 2015 May; 34(5):e113-8. PubMed ID: 25876102
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Meningococcal B vaccine: new drug. The only vaccine against some serogroup B meningococci.
    Prescrire Int; 2008 Jun; 17(95):95-7. PubMed ID: 18623907
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety and immunogenicity of meningococcus serogroup C conjugate vaccine administered as a primary or booster vaccination to healthy four-year-old children.
    McVernon J; Maclennan J; Buttery J; Oster P; Danzig L; Moxon ER
    Pediatr Infect Dis J; 2002 Aug; 21(8):747-53. PubMed ID: 12192163
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Seroprevalence of meningococcal serogroup C bactericidal antibodies in the Portuguese population, a decade after vaccine introduction in the National Immunisation Programme.
    Gonçalves P; Sáez-López E; Carneiro S; Simões MJ
    PLoS One; 2021; 16(4):e0250103. PubMed ID: 33857245
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antibody persistence after serogroup C meningococcal conjugate immunization of United Kingdom primary-school children in 1999-2000 and response to a booster: a phase 4 clinical trial.
    Perrett KP; Winter AP; Kibwana E; Jin C; John TM; Yu LM; Borrow R; Curtis N; Pollard AJ
    Clin Infect Dis; 2010 Jun; 50(12):1601-10. PubMed ID: 20459323
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combined Haemophilus influenzae type b and Neisseria meningitidis serogroup C (HibMenC) or serogroup C and Y-tetanus toxoid conjugate (and HibMenCY) vaccines are well-tolerated and immunogenic when administered according to the 2,3,4 months schedule with a fourth dose at 12-18 months of age.
    Habermehl P; Leroux-Roels G; Sänger R; Mächler G; Boutriau D
    Hum Vaccin; 2010 Aug; 6(8):640-51. PubMed ID: 20697200
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Different Dynamics for IgG and IgA Memory B Cells in Adolescents following a Meningococcal Serogroup C Tetanus Toxoid Conjugate Booster Vaccination Nine Years after Priming: A Role for Priming Age?
    Stoof SP; Buisman AM; van Rooijen DM; Boonacker R; van der Klis FR; Sanders EA; Berbers GA
    PLoS One; 2015; 10(10):e0138665. PubMed ID: 26458006
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunogenicity and Safety of a Quadrivalent Meningococcal ACWY-tetanus Toxoid Conjugate Vaccine 6 Years After MenC Priming as Toddlers.
    Nolan T; Booy R; Marshall HS; Richmond P; Nissen M; Ziegler JB; Baine Y; Traskine M; Jastorff A; Van der Wielen M
    Pediatr Infect Dis J; 2019 Jun; 38(6):643-650. PubMed ID: 31116180
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Investigation of serum bactericidal activity in childhood and adolescence 3-6 years after vaccination with a single dose of serogroup C meningococcal conjugate vaccine.
    Sakou II; Tzanakaki G; Tsolia MN; Sioumala M; Barbouni A; Kyprianou M; Papaevangelou V; Tsitsika A; Blackwell CC; Kafetzis D; Kremastinou J
    Vaccine; 2009 Jul; 27(33):4408-11. PubMed ID: 19500554
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.